Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 6/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28949956 | 1.00 | SMPD1 (0.53) | SMPD1SLC6A5MEN1KMT2APTPN11 | |
| SCHEMBL6111633 | 1.00 | SMPD1 (0.53) | SMPD1SLC6A5MEN1KMT2APTPN11 | |
| SCHEMBL969363 | 1.00 | SMPD1 (0.53) | SMPD1SLC6A5MEN1KMT2APTPN11 | |
| SCHEMBL28599541 | 0.98 | SMPD1 (0.51) | SMPD1SLC6A5MEN1KMT2A | |
| SCHEMBL10822455 | 0.91 | SLC6A5 (0.57) | SMPD1SLC6A5MEN1KMT2AMAPT | |
| SCHEMBL10822447 | 0.91 | SLC6A5 (0.57) | SMPD1SLC6A5MEN1KMT2AMAPT | |
| SCHEMBL30937962 | 0.88 | SMPD1 (0.53) | SMPD1SLC6A5MEN1KMT2ALMNA | |
| SCHEMBL30937964 | 0.88 | SMPD1 (0.53) | SMPD1SLC6A5MEN1KMT2ALMNA | |
| SCHEMBL12355826 | 0.86 | PTPN11 (0.52) | SMPD1PTPN11 | |
| SCHEMBL1889108 | 0.85 | SMPD1 (0.51) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994423-B2 | Charge-transport materials, methods of fabrication thereof, and methods of use thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2234991-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | Georgia Tech Research Corporation (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080797-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090065057-A1 | Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | GEORGIA TECH RESEARCH CORPORATION | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | SLCO1B3, SLCO4C1, SLCO2B1 | SMPD1 4884/4885SLC6A5 195/4885MEN1 2411/4885 |
| US-20090065057-A1 | Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | SLC9A3, SLC18A2, SLC9A2 | SMPD1 3884/4885SLC6A5 35/4885MEN1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.